These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32245484)

  • 1. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
    Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
    Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
    Wang F; Travins J; DeLaBarre B; Penard-Lacronique V; Schalm S; Hansen E; Straley K; Kernytsky A; Liu W; Gliser C; Yang H; Gross S; Artin E; Saada V; Mylonas E; Quivoron C; Popovici-Muller J; Saunders JO; Salituro FG; Yan S; Murray S; Wei W; Gao Y; Dang L; Dorsch M; Agresta S; Schenkein DP; Biller SA; Su SM; de Botton S; Yen KE
    Science; 2013 May; 340(6132):622-6. PubMed ID: 23558173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
    Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
    Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
    Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
    Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.
    Chen J; Yang J; Sun X; Wang Z; Cheng X; Lu W; Cai X; Hu C; Shen X; Cao P
    Sci Rep; 2017 Nov; 7(1):16458. PubMed ID: 29184081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale design of novel substituted 1,3,5-triazine candidates as dual IDH1(R132H)/ IDH2(R140Q) inhibitors with high selectivity against acute myeloid leukemia: In vitro and in vivo preclinical investigations.
    Tawfik HO; Mousa MHA; Zaky MY; El-Dessouki AM; Sharaky M; Abdullah O; El-Hamamsy MH; Al-Karmalawy AA
    Bioorg Chem; 2024 Aug; 149():107483. PubMed ID: 38805913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH2/R140Q mutation confers cytokine-independent proliferation of TF-1 cells by activating constitutive STAT3/5 phosphorylation.
    Yang J; Chen J; Chang J; Sun X; Wei Q; Cai X; Cao P
    Cell Commun Signal; 2024 Feb; 22(1):116. PubMed ID: 38347540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant
    Goldberg L; Negi V; Chung YJ; Onozawa M; Zhu YJ; Walker RL; Pierce R; Patel DP; Krausz KW; Gonzalez FJ; Goodell MA; Rodriguez BAT; Meltzer PS; Aplan PD
    Cancer Res; 2021 Oct; 81(19):5033-5046. PubMed ID: 34321240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
    Huang R; Liao X; Li J; Wei J; Su X; Lai X; Liu B; Zhu F; Huang Y; Li Q
    Oncol Rep; 2019 May; 41(5):2876-2888. PubMed ID: 30896832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of novel 2-arylbenzimidazoles as selective mutant isocitrate dehydrogenase 2 R140Q inhibitors.
    Li Z; Wu X; Jia L; Li J; Zhang R; Tang H; Li Z; Bu H; Shen C
    Bioorg Med Chem Lett; 2020 May; 30(9):127070. PubMed ID: 32143887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design, synthesis and bioactivity evaluation of macrocyclic inhibitors of mutant isocitrate dehydrogenase 2 (IDH2) displaying activity in acute myeloid leukemia cells.
    Che J; Huang F; Zhang M; Xu G; Qu B; Gao J; Chen B; Zhang J; Ying H; Hu Y; Hu X; Zhou Y; Gao A; Li J; Dong X
    Eur J Med Chem; 2020 Oct; 203():112491. PubMed ID: 32679449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
    Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
    Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel enasidenib analogues targeting inhibition of mutant isocitrate dehydrogenase 2 as antileukaemic agents.
    Khalil AF; El-Moselhy TF; El-Bastawissy EA; Abdelhady R; Younis NS; El-Hamamsy MH
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2157411. PubMed ID: 36629449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
    Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
    Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of new IDH2
    Chen X; Wu X; Gao J; Ying H; Dong X; Che J; Shen Z
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000063. PubMed ID: 33184958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic
    Yen K; Travins J; Wang F; David MD; Artin E; Straley K; Padyana A; Gross S; DeLaBarre B; Tobin E; Chen Y; Nagaraja R; Choe S; Jin L; Konteatis Z; Cianchetta G; Saunders JO; Salituro FG; Quivoron C; Opolon P; Bawa O; Saada V; Paci A; Broutin S; Bernard OA; de Botton S; Marteyn BS; Pilichowska M; Xu Y; Fang C; Jiang F; Wei W; Jin S; Silverman L; Liu W; Yang H; Dang L; Dorsch M; Penard-Lacronique V; Biller SA; Su SM
    Cancer Discov; 2017 May; 7(5):478-493. PubMed ID: 28193778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Drug Design of Novel Triaminotriazine Derivatives as Orally Bioavailable IDH2
    Wei Q; Yao K; Yang J; Zhou Q; Liu P; Chen J; Liu H; Lai Y; Cao P
    J Med Chem; 2023 Sep; 66(18):12894-12910. PubMed ID: 37706660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.
    Ma R; Yun CH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2912-2917. PubMed ID: 30131249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia.
    Dogra R; Bhatia R; Shankar R; Bansal P; Rawal RK
    Anticancer Agents Med Chem; 2018; 18(14):1936-1951. PubMed ID: 30360730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a novel class of pyridine derivatives that selectively inhibits mutant isocitrate dehydrogenase 2.
    Wang F; Li Z; Zhang T; Yan G; Hu M; Zhao L; Zhao Y; Chen Y
    Chem Biol Drug Des; 2018 Jun; 91(6):1087-1093. PubMed ID: 29120536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.